Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCD | O00767 | 3/20 | 0.54 |
| ▸ | PDE5A | O76074 | 4/20 | 0.53 |
| ▸ | AURKA | O14965 | 2/20 | 0.53 |
| ▸ | FYN | P06241 | 2/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.43 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.42 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.42 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4059875 | 0.86 | PDE5A (0.62) | PDE5AAURKAPDE10AIKBKETBK1 | |
| SCHEMBL4051632 | 0.83 | SCD (0.53) | SCDPDE5AAURKAAURKBTBK1 | |
| SCHEMBL4049683 | 0.83 | SCD (0.62) | SCDAURKATBK1 | |
| SCHEMBL13607947 | 0.83 | FYN (0.49) | SCDPDE5AFYNPTGS2KCNH2 | |
| SCHEMBL4055992 | 0.82 | AURKA (0.68) | SCDAURKAIKBKEAURKBTBK1 | |
| SCHEMBL4061801 | 0.82 | PDE5A (0.54) | PDE5AAURKAFYNPDE10AIKBKE | |
| SCHEMBL4061729 | 0.81 | AURKA (0.57) | SCDAURKAPTGS2IKBKEAURKB | |
| SCHEMBL4055971 | 0.79 | AURKA (0.56) | PDE5AAURKAFYNIKBKEAURKB | |
| SCHEMBL4051168 | 0.79 | PDE5A (0.58) | SCDPDE5AAURKAPDE10A | |
| SCHEMBL4060342 | 0.78 | PDE5A (0.57) | PDE5AAURKAPDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7622479-B2 | Bicyclic derivative, its production and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-11-24 | — | — | US | disclosed |
| US-20050101647-A1 | Bicyclic derivative, its production and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-05-12 | — | — | US | disclosed |
| EP-1460067-A1 | BICYCLIC DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE | Takeda Chemical Industries, Ltd. (JP) | 2004-09-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050101647-A1 | Bicyclic derivative, its production and use | ABL1, SRC, PTK2B | SCD 4559/4885PDE5A 2762/4885AURKA 247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.